Ascendis Pharma Seeing 'Good Progress' in Achondroplasia Programs, Wedbush Says

MT Newswires Live

Aug 07

Ascendis Pharma (ASND) is seeing "good progress" in its Achondroplasia or ACH programs, with positive data on product candidates and accelerating uptake of its newly launched Yuviwel therapy, Wedbush Securities said in a Thursday note.

The company issued an update on its ACH programs the same day, reporting 78-week data from a phase 2 study of the combination of TransCon CNP and TransCon hGH in patients with ACH. The results indicate the combination therapy's potential to yield a strong long-term clinical benefit, Wedbush said.

Ascendis Pharma is planning a phase 3 trial to compare the combination therapy with TransCon CNP alone, the brokerage added.

Meanwhile, Yuviwel patient enrollments rose nearly 200% in two months, potentially generating Q2 net revenue that would top the consensus forecast of 4.4 million euros ($5.1 million), Wedbush added.

Wedbush has an outperform rating and $327 price target on Ascendis Pharma.

Price: 249.63, Change: +5.43, Percent Change: +2.22

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2657655054"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657655054\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657655054?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 00:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657655054","market":"sh","top_or_hot":-1,"title":"Ascendis Pharma Seeing 'Good Progress' in Achondroplasia Programs, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> Ascendis Pharma (ASND) is seeing \"good progress\" in its Achondroplasia or ACH programs, with positive data on product candidates and accelerating uptake of its newly launched Yuviwel therapy, Wedbush Securities said in a Thursday note.</p><p>The company issued an update on its ACH programs the same day, reporting 78-week data from a phase 2 study of the combination of TransCon CNP and TransCon hGH in patients with ACH. The results indicate the combination therapy's potential to yield a strong long-term clinical benefit, Wedbush said.</p><p>Ascendis Pharma is planning a phase 3 trial to compare the combination therapy with TransCon CNP alone, the brokerage added.</p><p>Meanwhile, Yuviwel patient enrollments rose nearly 200% in two months, potentially generating Q2 net revenue that would top the consensus forecast of 4.4 million euros ($5.1 million), Wedbush added.</p><p>Wedbush has an outperform rating and $327 price target on Ascendis Pharma.</p><p>Price: 249.63, Change: +5.43, Percent Change: +2.22</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascendis Pharma Seeing 'Good Progress' in Achondroplasia Programs, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscendis Pharma Seeing 'Good Progress' in Achondroplasia Programs, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-07 00:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Ascendis Pharma (ASND) is seeing \"good progress\" in its Achondroplasia or ACH programs, with positive data on product candidates and accelerating uptake of its newly launched Yuviwel therapy, Wedbush Securities said in a Thursday note.</p><p>The company issued an update on its ACH programs the same day, reporting 78-week data from a phase 2 study of the combination of TransCon CNP and TransCon hGH in patients with ACH. The results indicate the combination therapy's potential to yield a strong long-term clinical benefit, Wedbush said.</p><p>Ascendis Pharma is planning a phase 3 trial to compare the combination therapy with TransCon CNP alone, the brokerage added.</p><p>Meanwhile, Yuviwel patient enrollments rose nearly 200% in two months, potentially generating Q2 net revenue that would top the consensus forecast of 4.4 million euros ($5.1 million), Wedbush added.</p><p>Wedbush has an outperform rating and $327 price target on Ascendis Pharma.</p><p>Price: 249.63, Change: +5.43, Percent Change: +2.22</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657655054","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657655054","pubTimestamp":1786032317,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ascendis Pharma  is seeing \"good progress\" in its Achondroplasia or ACH programs, with positive data on product candidates and accelerating uptake of its newly launched Yuviwel therapy, Wedbush Securities said in a Thursday note.The company issued an update on its ACH programs the same day, reporting 78-week data from a phase 2 study of the combination of TransCon CNP and TransCon hGH in patients with ACH. The results indicate the combination therapy's potential to yield a strong long-term clinical benefit, Wedbush said.Ascendis Pharma is planning a phase 3 trial to compare the combination therapy with TransCon CNP alone, the brokerage added.Meanwhile, Yuviwel patient enrollments rose nearly 200% in two months, potentially generating Q2 net revenue that would top the consensus forecast of 4.4 million euros , Wedbush added.Wedbush has an outperform rating and $327 price target on Ascendis Pharma.Price: 249.63, Change: +5.43, Percent Change: +2.22","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4097":"系统软件","BK4139":"生物科技","ASND":"Ascendis Pharma A/S","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","MEDI":"HARBOR HEALTH CARE ETF","PRGS":"Progress Software Corporation"},"translate_title":"韦德布什表示，Ascendis Pharma 在软骨发育不全项目方面取得了“良好进展”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDI":0.6,"PRGS":1.5,"ASND":1},"content_text":"Ascendis Pharma (ASND) is seeing \"good progress\" in its Achondroplasia or ACH programs, with positive data on product candidates and accelerating uptake of its newly launched Yuviwel therapy, Wedbush Securities said in a Thursday note.The company issued an update on its ACH programs the same day, reporting 78-week data from a phase 2 study of the combination of TransCon CNP and TransCon hGH in patients with ACH. The results indicate the combination therapy's potential to yield a strong long-term clinical benefit, Wedbush said.Ascendis Pharma is planning a phase 3 trial to compare the combination therapy with TransCon CNP alone, the brokerage added.Meanwhile, Yuviwel patient enrollments rose nearly 200% in two months, potentially generating Q2 net revenue that would top the consensus forecast of 4.4 million euros ($5.1 million), Wedbush added.Wedbush has an outperform rating and $327 price target on Ascendis Pharma.Price: 249.63, Change: +5.43, Percent Change: +2.22","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}